Product Description
Brincidofovir is an alkoxyalkyl ester prodrug containing the synthetic, acyclic nucleoside monophosphate analog cidofovir linked, through its phosphonate group, to a lipid, 3-hexadecyloxy-1-propanol, with antiviral activity against double-stranded DNA viruses. Upon oral administration, brincidofovir crosses the intestinal wall and penetrates target viral-infected cells before being cleaved to the free antiviral agent cidofovir. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Brincidofovir)
Mechanisms of Action: DNA Polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: Smallpox
Known Adverse Events: Abdominal Pain | Pain Unspecified | Diarrhea
Company: Chimerix
Company Location: DURHAM NC 27713
Company CEO: Michael A. Sherman
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Hong Kong, Japan, Korea, Singapore, South Korea, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 2: Kidney Transplant|Lymphoma|T-Cell Peripheral Lymphoma
Phase 1: Papilloma|Smallpox
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2061240096 | P2 |
Recruiting |
Lymphoma |
2029-07-31 |
|
| BCV-NL01 | P2 |
Recruiting |
T-Cell Peripheral Lymphoma |
2027-10-23 |
|
| jRCT2041220056 | P2 |
Recruiting |
Kidney Transplant |
2024-12-31 |
|
| BCV-001 | P1 |
Completed |
Smallpox |
2023-08-14 |